Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

Dimerix will receive an upfront payment of $30m from Amicus and up to $75m in development and regulatory milestone payments.

The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Kidney drug developer Dimerix has struck a partnering deal with a Nasdaq listed company that could deliver more than $1 ...

The FDA pushed back its decision date on Cytokinetics heart drug, while AstraZeneca got Phase 3 trial results that could help ...

Ainsworth Game Technology (ASX:AGI) jumped 32.4% since Thursday 24 April, finishing the week at 98 cents after announcing it ...

In one of the largest licensing deals in the Australian biotech industry, Dimerix Limited (ASX: DXB) has sealed an exclusive ...

These shares are having a good finish to the week. Let's find out why. The post Why Boss Energy, Capstone, Dimerix, and ...

Dimerix Ltd. sealed an exclusive license agreement with Amicus Therapeutics Inc. for commercialization of its phase III kidney disease candidate, DMX-200, in a deal valued at AU$940 million (US$601.22 ...

Dimerix (ASX: DXB), an Australian drug developer, has entered into an exclusive US licensing agreement with Amicus ...